摘要
目的:探讨托伐普坦治疗顽固性心力衰竭的效果。方法:收治顽固性心力衰竭患者158例,分为对照组和研究组。对照组采用常规治疗,研究组在对照组基础上加用托伐普坦,比较两组24 h尿量、左室射血分数(LVEF)、N末端B型利尿肽前体(NT-pro BNP)及血钠水平。结果:治疗后两组24 h尿量、LVEF、NT-pro BNP及研究组的血钠值均比治疗前显著改善(P<0.05),治疗后研究组24 h尿量、LVEF、NT-pro BNP、血钠值显著优于对照组(P<0.05)。两组均无显著不良反应发生。结论:托伐普坦治疗顽固性心力衰竭可显著提升心功能和血钠水平,保障临床疗效。
Objective:To explore the effect of tolvaptan in the treatment of refractory heart failure.Methods:158 patients with refractory heart failure were selected.They were divided into the control group and the study group.The control group was treated with conventional therapy.The study group was treated with tolvaptan on the basis of the control group.We compared the 24 hours urine volume,left ventricular ejection fraction(LVEF),N terminal B type natriuretic peptide(NT-pro BNP) and serum sodium levels of the two groups.Results:After treatment,the 24 hours urine volume,LVEF,NT-pro BNP of the two groups and blood sodium in the study group were significantly improved than before treatment(P<0.05),after treatment,the 24 hours urine volume,LVEF,NT-pro BNP and blood sodium in the study group were significantly better than those in the control group(P<0.05).Conclusion:Tolvaptan treatment for intractable heart failure can significantly enhance the level of cardiac function and serum sodium and guarantee the clinical curative effect.
出处
《中国社区医师》
2018年第4期63-64,共2页
Chinese Community Doctors
